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Abstract
Background: We hypothesize that the prevalence of unknown heart failure in diabetic patients
aged 60 years and over is relatively high (15% or more) and that a cost-effective strategy can be
developed to detect heart failure in these patients. The strategy is expected to include some signs
and symptoms (such as dyspnoea, orthopnoea, pulmonary crepitations and laterally displaced apical
beat), natriuretic peptide measurements (Amino-terminal B-type natriuretic peptide) and possibly
electrocardiography. In a subset of patients straightforward echocardiography may show to be
cost-effective. With information from our study the detection of previously unknown heart failure
in diabetic patients could be improved and enable the physician to initiate beneficial morbidity and
mortality reducing heart failure treatment more timely.
Primary objectives: - To assess the prevalence of (previously unrecognised) heart failure in
primary care patients with diabetes type 2.
- To establish the most cost-effective diagnostic strategy to detect unrecognised heart failure in
these patients.
Secondary objectives: - To assess the impact of heart failure, and the combination of a new
diagnosis with accordingly treatment in patients with diabetes type 2 on health status.
Methods/Design: Design: A prospective diagnostic efficiency study.
Patient population: Patients aged 60 years and older with diabetes type 2 from primary care,
enlisted with the diabetes service of the Diagnostic Center in Etten-Leur (SHL)
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All participants will be investigated at the cardiology out-patient department of the regional hospital
(Oosterschelde Hospital in Goes, Zeeland, the Netherlands) during a single 1.5 hour standardised
diagnostic assessment, including history taking, physical examination, electrocardiography,
echocardiography, blood tests, and Health status questionnaires. Patients will be asked if we can
contact them afterwards for follow-up and for repeating the questionnaires after three and 12
months.
Main study parameters/endpoints: Prevalence (with exact 95% confidence intervals) of (previously
unrecognised) heart failure (systolic and 'isolated' diastolic) and the diagnostic value of signs and
symptoms, NT-proBNP, electrocardiography and a combination of these items. The cost-
effectiveness of different diagnostic strategies. Impact of heart failure and the combination of a new
diagnosis with accordingly treatment on health status.
Trial registration: CCMO register NL2271704108
Background
Cardiovascular diseases account for up to 80% of the
excess mortality in patients with diabetes type 2 (DM2)
[1]. Processes underlying this excess cardiovascular risk
include coronary atherosclerosis, microvascular disease
and autonomic neuropathy [1]. Importantly, morpholog-
ical myocardial abnormalities and eventually diabetic car-
diomyopathy and heart failure (HF), i.e. left ventricular
dysfunction with symptoms of heart failure play a role
[2,3]. Notwithstanding the high rate of cardiovascular dis-
eases and the availability of morbidity and mortality
reducing treatment for heart failure, [4] up to now, only a
few studies assessed the prevalence of HF in diabetic
patients. These studies showed a prevalence of HF of 12-
22% in the subgroup of diabetic patients who had been
admitted to the hospital [5,6]. In another study, the inci-
dence rate of HF in DM2 patients was about 2.5 times
higher than in non-diabetic control subjects [7]. Impor-
tantly, the diagnosis of HF in the aforementioned studies
was based on hospital discharge diagnoses. To our knowl-
edge, there are no studies that assessed HF using a diag-
nostic strategy including echocardiography in a
representative sample of patients with diabetes in primary
care (not selectively in those admitted to a hospital) [8,9].
Hence, valid prevalence estimates of HF in patients with
diabetes type 2 are lacking. Such studies are needed
because the majority of patients with diabetes is managed
in primary care [10]. The diagnosis of HF however is noto-
riously difficult in the early phases of the syndrome and in
the presence of co morbidities, such as chronic obstructive
pulmonary disease (COPD) and obesity [11]. Moreover,
echocardiography, the cornerstone investigation to diag-
nose HF, [4] is usually not ready at hand for primary care
patients. Studies indicate that 50% of all patients (thus
not only those with DM2) with HF in primary care remain
undetected [10]. Recently, our group showed that unrec-
ognised HF was common (prevalence 20.5%) among pri-
mary care patients with COPD aged ≥ 65 years [12]. High
prevalence of unrecognised HF can therefore also be
expected in patients with diabetes in primary care.
We hypothesize that the prevalence of unknown heart
failure in diabetic patients aged 60 years and over is rela-
tively high (15% or more). Our study will provide valid
and precise prevalence estimates of previously unrecog-
nised HF in DM2 patients (relevant for secondary preven-
tion). Comparison of different combinations of
diagnostic tests to recognise HF will reveal the most cost-
effective strategies to detect HF in patients with DM2. The
strategy is expected to include some signs and symptoms
(such as dyspnoea, orthopnoea, pulmonary crepitations,
laterally displaced apical beat), B-type natriuretic peptide
measurements (NT-proBNP)), and possibly electrocardi-
ography. In a subset of patients straightforward echocardi-
ography may prove to be cost-effective.
With information from our study the detection of previ-
ously unknown heart failure in diabetes patients can be
improved, enabling the physician to initiate beneficial
morbidity and mortality reducing heart failure treatment
more timely.
Primary objectives
- To assess the prevalence of (previously unrecognised) HF
in primary care patients with diabetes type 2 (DM 2).
- To establish the most cost-effective diagnostic strategy to
detect unrecognised HF in these patients.
Secondary objectives
- To assess the impact of heart failure, and the combina-
tion of new diagnosis of HF with accordingly treatment in
patients with diabetes type 2 on health status.
Methods/design
Study design
A prospective diagnostic efficiency study. See figure 1 for
the study scheme and table 1 for the measurement
scheme.BMC Public Health 2009, 9:479 http://www.biomedcentral.com/1471-2458/9/479
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Study population
Patients aged 60 years and over with diabetes type 2,
enlisted with the diabetes service of the Center for Diag-
nostic Support in Primary Care (SHL), Etten-Leur are eli-
gible. This is a representative sample of all patients with
diabetes type 2 registered with a general practitioner. The
standard care of the diabetes service consists of periodi-
cally serum glucose and HbA1c assessment and yearly
monitoring of other laboratory parameters and fundos-
copy, to help the general practitioners with the manage-
ment of patients with diabetes. Furthermore, the SHL
provides a supporting service to the general practitioners
of diabetic nurses, who work according to the current dia-
betes guidelines.
In total 561 general practitioners in the region make use
of the services of the Diabetic service of the SHL, with
48,175 patients with type 2 diabetes enlisted in the SHL
service. In total, 100 nurse practitioners from the SHL sup-
port more than 200 general practitioners (GPs) in their
work for diabetic patients. A random sample of approxi-
mately 1200 patients enlisted within the SHL diabetic
service database and living within 60 kilometres of the
cardiology outpatient department of the Oosterschelde
hospital in Goes will be asked to participate in the study.
To prevent duplicate investigations, patients known with
a cardiologist-confirmed diagnosis of heart failure, will
only be asked to fill out the questionnaires. They also will
be asked for permission to scrutinize their medical files
for co-morbidities and date of diagnosis of heart failure.
The expected prevalence rate of already known HF is less
than 5% (30 of the 600 responders).
Power calculation
When the diagnostic value of several diagnostic variables
or tests together needs to be quantified, no straightfor-
ward methods to estimate the required sample size are
available. A 'rule of thumb' for each diagnostic determi-
nant included in the analysis is at least 10 events in the
smallest category (in our study those with heart failure) is
recommended. Our study will include at the most 9 diag-
nostic determinants (e.g. items from history and physical
examination summarised in a score, ECG, and NT-
proBNP). Thus, 90 patients with previously unknown
heart failure would be required. With an estimated preva-
lence rate of 15% of previously unknown heart failure,
about 600 diabetic type 2 patients should participate.
Assuming, based on previous experiences, a response rate
of at least 50%, approximately 1200 patients will be
invited.
Patient invitation
Eligible patients receive an information letter with infor-
mation about the study, and they are asked to send their
answer back. If the patient is interested in the study, the
patient receives detailed information about the study.
Patients who are not willing to take part in the study will
be asked for the reasons for not participating.
Patient consent
Patients that are invited to participate in this study are
entitled to choose whether or not to take part. Their deci-
sion will be voluntary and they should be competent to
understand what the study involves. The information pro-
vided will be in the patient's own language.
Documentation of consent
Written informed consent is obtained before any study
procedure will be undertaken. The written consent form
will be signed and dated by each participant and the
researcher.
Diagnostic assessment
All participants will be investigated at the cardiology out-
patient department of the regional hospital (Ooster-
schelde Hospital in Goes, the Netherlands) during a single
1.5 hour standardised diagnostic assessment. The diag-
nostic measurements include: history taking (e.g. orthop-
noea), physical examination (e.g. pulmonary crepitations,
laterally displaced apical beat), electrocardiography, and
echocardiography. Plasma B-type natriuretic peptide
measurements, glucose levels, creatinin levels, and
Study scheme Figure 1
Study scheme.
ȱ
ȱ
InformingȱGPsȱ
ȱ
ȱ
Recruitmentȱpatientsȱ
ȱ
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HbA1C will be measured a few days later at a local 'medi-
cal checkpoint' in the neighbourhood of the participant,
during their regular blood sample taking for the diabetes
service. Signs and symptoms will be assessed by a trained
physician in a standardised manner. The clinical findings
will be combined in a 'clinical score' [13]. Present medica-
tion use is asked for and will be checked, patients will be
asked to take their medication to the outpatient depart-
ment. Medical history and time since diagnosis of diabe-
tes with all diabetes related and not-related (e.g. NSAIDs)
medication will be checked in the electronic medical files
of the general practitioners (GPs). Blood samples (20 ml)
will be taken and after centrifugation specimens of plasma
and cells will be stored at -70 degrees Celsius. B-type natri-
uretic peptides (BNP and NTproBNP) are released pre-
dominantly from the ventricular myocardium in response
to myocardial stretch, such as in heart failure [14]. The
plasma level of both BNP and the release split product
amino-terminal proBNP (NT-proBNP) are closely related
to left ventricular function [15]. We will measure NT-
proBNP levels from plasma using a non-competitive
immunoradiometric assay (Roche Inc., Germany).
A standard 12-lead electrocardiogram (ECG) will be
recorded and classified according to the Minnesota coding
criteria by an experienced and trained cardiologist.
Echocardiography will be performed with a General Elec-
tric, Vivid 7 imaging system by an experienced cardiac
sonographer. All echocardiographic images will be
recorded and interpreted by a cardiologist, who is blinded
Table 1: Measurement Scheme
baseline 3 
months
12 
months
VISIT 1
Informed Consent X
Diagnostic assessment
History taking X
Physical examination X
ECG X
NT-proBNP X
Other laboratory assessments 
(HbA1C, Fasting Glucose, plasma creatinin, ureum; hsCRP, Hb, Ht)
X
Echo X
Questionnaire patient number of 
items
Demographic parameters X
Diabetes Health Profile 32 X X X
SF36 36 X X X
EQ5D 06 X X X
Medication use XXX
Diagnostic centre and GP registration
Medical history X
Medical costs XBMC Public Health 2009, 9:479 http://www.biomedcentral.com/1471-2458/9/479
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to clinical data. Parameters from M-mode and two-
dimensional echocardiography with Doppler analysis will
be applied. The left ventricular ejection fraction (LVEF)
will be assessed quantitatively or semi-quantitatively,
when necessary. Diastolic function will be assessed by an
integrated combination of Doppler measurements of the
mitral inflow and Doppler tissue imaging (DTI) of the
mitral annulus [16]. Inclusion of DTI creates the possibil-
ity to measure left ventricular relaxation and filling pres-
sures load independently in a reproducible and feasible
way [16-23].
Reference standard of heart failure
Presence or absence of HF will be determined by an out-
come panel consisting of two cardiologists and one GP. In
analogy with earlier studies, the panel will use all availa-
ble information from the diagnostic work-up, including
echocardiography, but except the NT-proBNP results (to
prevent incorporation bias pertaining to this particular
test). Consensus diagnosis by an outcome panel is an
established method in case an irreproachable reference
standard is lacking, as is the case for HF [8,9]. Outcome
panels have been successfully applied in earlier studies of
HF by our group and the reproducibility of this method is
high [13]. In case of no consensus the majority decision
will be used. Patients classified as HF by the panel will be
further classified as systolic or 'isolated' diastolic heart
failure or 'isolated' right sided heart failure. For systolic
heart failure, patients have to have an echocardiographic
left ventricular ejection fraction ≤ 45% in combination
with presence of symptoms indicative of heart failure
(that is, orthopnoea, paroxysmal nocturnal dyspnoea,
fatigue, peripheral oedema, nocturia more than twice a
night, or any combination of these symptoms). For iso-
lated diastolic ventricular dysfunction, patients have to
have echocardiographic diastolic dysfunction and a left
ventricular ejection fraction > 45%. For isolated diastolic
heart failure patients have to have echocardiographic
diastolic abnormalities in combination with indicative
symptoms and signs (that is, peripheral or pulmonary
fluid retention or raised jugular venous pressure) of heart
failure [24] or indicative symptoms and echocardio-
graphic left ventricular hypertrophy, atrial fibrillation, or
anginal complaints [25].
Assessment of diabetes
All patients registrated in the diabetic service of SHL have
been diagnosed with diabetes according to the Diabetes
Guidelines. The diagnosis diabetes was established if on
two different days the fasting glucose level was above cut-
off levels (6.0 mmol/l in capillary blood or 6.9 mmol/l in
venous plasma or non-fasting glucose level > 11.0 mmol/
l) or one glucose level > 11.0 mmol/l in combination with
symptoms of hyperglycaemia, such as itching, thirst etc.
Health status measurement
To assess the impact of (detecting and treating previously
unknown) heart failure on the health status the partici-
pants will receive a questionnaire (including questions on
health status) to be completed during their visit to the
diagnostic centre at baseline. The group known with a car-
diologist-confirmed diagnosis of heart failure will be vis-
ited at home. After 3 months and after 12 months from
baseline measurement the participants will receive the
same questionnaires, including an additional question-
naire with questions about possible change in medica-
tion.
In order to calculate quality-adjusted life years (QALYs)
preference-based utilities will be measured with the Euro-
Qol-5D instrument [26]. Generic health status will be
assessed with the Short Form 36 (SF36) [27-29]. For dis-
ease specific health status the diabetes health profile
(DHP) will be used [30]. These questionnaires are all
widely tested and used.
Cost-effectiveness analysis
A cost-effectiveness analysis of different strategies to detect
unrecognized HF in patients with type 2 diabetes will be
performed based on a social perspective according to
international and national guidelines [31]. As a result of
the primary data-analysis, various diagnostic strategies
will be identified which differ in terms of the tests that are
performed, the order of the tests, and the cut-off points
used. Each strategy and each cut-off-point leads to differ-
ent numbers of patients who are diagnosed as true posi-
tive (TP), false positive (FP), true negative (TN) and false
negative (FN). To estimate the costs associated with these
categories (FP, TP, FN, TN) a previously used and vali-
dated Markov model will be applied. The various strate-
gies will be ranked by increasing cost-effectiveness ratios;
the most optimal strategy in terms of cost effectiveness
will be defined. It is important to note that there may be
discrepancies in the most effective diagnostic strategy and
the most cost-effective diagnostic strategy. The incremen-
tal cost-effectiveness of those tests that add to the best
available diagnostic strategy, compared to the sub-opti-
mal diagnostic strategy is of importance, in other words
the additional value of the more expensive and most dis-
criminating tests. For measuring direct costs, resource
quantities are collected from the case record forms, and
prices will be based on market prices or tariffs for the
investigations performed in the study. Only relevant indi-
rect medical costs are taken into consideration such as
patient time and travel costs. When comparing diagnostic
strategies, however, indirect costs are less relevant because
all investigations can be performed in a single setting at
the outpatient department, irrespective of the number of
investigations. Both absolute costs and incremental costsBMC Public Health 2009, 9:479 http://www.biomedcentral.com/1471-2458/9/479
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of different diagnostic strategies will be taken in consider-
ation.
A sensitivity-analysis will be performed in order to esti-
mate the susceptibility of cost-effectiveness ratio's to vari-
ation in prior assumptions and choices, including a 'worst
case - best case' comparison.
Statistical analysis
Prevalence of (previously unrecognised) heart failure
(systolic and 'isolated' diastolic) will be calculated with
exact 95% confidence intervals. The crude association of
each diagnostic test (including the 'clinical score') with
the presence or absence of HF will first be quantified by
calculating predictive values, sensitivity, specificity and
likelihood ratios by using univariate logistic regression
analysis. Those with a p-value < 0.15 in the univariate
analysis will subsequently be included in a multivariate
logistic regression analyses to determine their independ-
ent contribution to the diagnosis of HF. In the analyses
the chronology in which investigations are performed in
practice will be followed. First of all, the diagnostic value
of the signs and symptoms score will be assessed. Then
NT-proBNP and ECG will be added, first separately and
then in different combinations, to quantify their added
diagnostic value, using the likelihood ratio test at a p-
value of < 0.10 [32]. Areas under the ROC curve will be
calculated for different combinations of the parameters to
further quantify the diagnostic accuracy. Echocardio-
graphic variables will not be evaluated separately on their
diagnostic value because they would likely receive an
overriding weight in the consensus judgement (i.e. diag-
nostic outcome assessment) [33]. In the cost-effective
analysis, however, a separate diagnostic strategy to detect
previously unrecognised HF by means of echocardiogra-
phy only, will be evaluated, based on the echocardio-
graphic findings. To assess the impact of heart failure, and
diagnosis and treatment of heart failure in diabetes type 2
patients on health status, the scores on the Health status
questionnaires of the three groups (no heart failure,
known heart failure and previously unknown heart fail-
ure) will be compared at baseline (t0) and on 3 months
and 12 months. Also the difference between 0-3 months,
3-12 months and 0-12 months within patients, will be
compared between the groups (T-test and ANOVA).
Regulatory authority approval
This study will be prepared, conducted and reported in
compliance with the Dutch Law on Medical research with
humans (WMO). The study will be conducted according
to the current version of the Declaration of Helsinki.
Ethics committee approval
The Medical Ethical Committee of the University Medical
Center Utrecht (METC) assessed and approved the proto-
col, the patient consent forms, the patient information let-
ters, and the letter to the General Practitioner.
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